Ketamine induced Schizophrenia Model Development Service

Are you currently facing complex challenges in central nervous system (CNS) drug development, such as a lack of translatable preclinical models for schizophrenia? Our ketamine-induced schizophrenia model development services help you accelerate drug discovery by providing a powerful, clinically relevant platform for screening next-generation therapeutics. This is achieved through our advanced understanding of glutamatergic pathways and comprehensive behavioral and biomarker assays.

Schizophrenia is a severe neuropsychiatric disorder with a significant unmet need for effective therapeutics, particularly for its negative and cognitive symptoms. The ketamine model has emerged as a superior preclinical tool by shifting focus from the traditional dopamine hypothesis to the more complex and clinically relevant glutamatergic system. By targeting the NMDA receptor and related pathways, it offers a more complete and translationally relevant platform for drug discovery.

How Our Ketamine-Induced Schizophrenia Model Development Services Can Assist Your Project

Our services are designed to address the core problem of finding effective treatments for schizophrenia's positive, negative, and cognitive symptoms. We provide a robust and validated platform to test the efficacy of your lead compounds. The specific deliverables and key problem-solving capabilities we offer include:

• Comprehensive Efficacy Testing: We can precisely quantify the ability of your compound to reverse key schizophrenia-like behaviors, including hyperlocomotion and deficits in social interaction and cognitive function.
• Mechanistic Validation: Our services go beyond simple behavioral readouts to provide deep insights into your compound's mechanism of action by integrating advanced neurochemical and neurophysiological assays.
• Translational Insights: By using models that directly mirror human disease pathology, we provide data that has a higher probability of translating to clinical success.

Discover How We Can Help - Request a Consultation

Workflow

• Required Starting Materials: To initiate a project, clients typically provide us with the following:

1. Your lead compound(s), including concentration, solubility, and storage requirements.
2. A brief summary of your compound's mechanism of action and therapeutic hypothesis.
3. Any relevant preliminary data, such as in vitro receptor binding assays or toxicity reports.

• Final Deliverables: Upon completion, you will receive:

1. A detailed final report with a summary of findings and expert interpretation.
2. Complete raw and analyzed behavioral data.
3. A comprehensive analysis of neurochemical and EEG biomarkers.

• Estimated Timeframe: The typical timeframe for this service ranges from 12 to 24 weeks, depending on the complexity of the study design, the number of compounds tested, and the specific assays included.

Why Choose Us?

Creative Biolabs leverages over 20 years of experience in CNS drug discovery, making us a leader in preclinical research. Our deep scientific knowledge, advanced methodologies, and commitment to partnership provide a distinct advantage. We don't just provide data; we provide a clear pathway to a breakthrough. Our models are validated with published data, ensuring your research is built on a foundation of scientific rigor.

Experience the Advantage - Get a Quote Today

Customer Reviews

• "[Reliable Data] Using CBL's ketamine-induced schizophrenia model development services in our research has significantly improved our ability to obtain reliable and translatable data, which was a major hurdle in our previous studies." - [Jn Sh], May 2025
• "[Enhanced Validation] The integration of their neurochemical and EEG biomarker analysis provided the mechanistic validation our team needed to confidently move our lead compound forward in the pipeline." - [Ma Kr], July 2025

Ketamine-Induced Schizophrenia Model

Ketamine, a non-competitive NMDA receptor antagonist, induces a full range of schizophrenia-like symptoms in animals. Beyond this direct antagonism, a more intricate molecular mechanism has been discovered. Ketamine inhibits the Plasma Membrane Calcium ATPase (PMCA), a key regulator of cellular calcium homeostasis. This inhibition leads to an increase in cytosolic calcium (Ca²⁺) and promotes excessive glutamate release. This process is mediated by the scaffolding protein PSD95, which organizes multiprotein complexes involving the NMDA receptor and PMCA, representing a more complete and novel mechanism of psychogenic action. Furthermore, combining the ketamine model with a neurodevelopmental challenge like social isolation creates a chronic and more clinically relevant model, better replicating the multifactorial nature of the human disease.

Fig.1 Animal behavior analysis in the open field test.¹

What We Can Offer

• Flexible & Customizable Study Design: Our services are a flexible, one-stop solution for preclinical studies. We can develop both acute and chronic models, including sophisticated combined pharmacological and neurodevelopmental paradigms, to precisely fit your compound's mechanism of action and your specific research questions.
• Integrated Upstream & Downstream Development: We offer a seamless process from initial model generation and validation to comprehensive behavioral phenotyping and biomarker analysis. Our streamlined workflow ensures efficient data acquisition and rapid, actionable insights.
• Advanced Behavioral & Translational Assays: Our extensive assay catalog and state-of-the-art facilities allow us to go beyond basic behavioral tests to provide in-depth analysis of cognitive, social, and physiological deficits.
• Adherence to Scientific Rigor: We are committed to the highest standards of scientific excellence. Our models and protocols are well-established, validated with published data, and follow strict quality control procedures to ensure the integrity and reproducibility of your data.
• Expert Team & Partnership: Our scientists and specialists work closely with you as a collaborative partner, providing expert guidance from the initial study design to the final report interpretation. We ensure that you receive not just data, but a clear path forward for your drug discovery program.

Related Services

In addition to our core services, we offer a range of complementary services that may be relevant to your project, including:

• Target Identification & Validation
• Compound Screening & Profiling
• Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
• Neuroinflammation Research Models

FAQs

The future of schizophrenia treatment depends on a new generation of targeted therapies. Contact us today to discuss how our services can accelerate your research and move you one step closer to a transformative cure.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Lisek, Malwina et al. "Glutamate Deregulation in Ketamine-Induced Psychosis-A Potential Role of PSD95, NMDA Receptor and PMCA Interaction." Frontiers in cellular neuroscience vol. 11 181. 28 Jun. 2017, doi:10.3389/fncel.2017.00181. Distributed under Open Access license CC BY 4.0, without modification.